Anti-Asthmatics And COPD Drugs Market Expected To Reach $111.34 Billion By 2030 As Growth Accelerates At 5.7% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Anti-Asthmatics And COPD Drugs Market Size And Revenue Forecast Through 2030
The market for anti-asthmatics and COPD drugs has experienced consistent expansion over the past few years. Valued at $85.08 billion in 2025, it is projected to reach $89.13 billion by 2026, reflecting a compound annual growth rate (CAGR) of 4.8%. This historical growth is driven by a higher incidence of asthma and COPD, escalating rates of smoking and air pollution, insufficient awareness of preventive treatments, the widespread presence of generic bronchodilators, and the strengthening of hospital pharmacy networks.
Over the coming years, the market for anti-asthmatics and COPD drugs is projected to see robust expansion. By 2030, its value is anticipated to reach $111.34 billion, reflecting a compound annual growth rate (CAGR) of 5.7%. This growth during the forecast period is driven by progress in biologics and monoclonal antibodies, the incorporation of artificial intelligence into treatment protocols, wider adoption of digital health tools, the rise of online pharmacy services, and the creation of specialized therapies aimed at severe COPD. Key developments expected in this period encompass personalized asthma care, telemedicine and remote monitoring of patients, the advent of inhalable biologics, an increased preference for combination drug regimens, and a focused effort on formulations for both pediatric and geriatric populations.
Download A Free Sample Report For Comprehensive Market Insights:
Anti-Asthmatics And COPD Drugs Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated expansion of the anti-asthmatics and COPD drugs market is significantly driven by the widespread prevalence of asthma-related conditions. Asthma is characterized as a chronic illness marked by airway inflammation and swelling, which constricts the passages responsible for transporting air from the nasal and oral cavities to the lungs. With the rising incidence of asthma cases, there has been a notable acceleration in the discovery of innovative anti-asthmatics and COPD drugs aimed at managing these respiratory disorders. For example, in June 2025, data from the UK-based Official Statistics agency revealed that emergency hospital admissions for asthma among adults aged 19 and over rose by 17% during the fiscal year ending 2024 compared to the preceding year. Consequently, the growing burden of asthmatic conditions fuels the creation of novel therapeutic agents, thereby propelling the forward momentum of the asthma drug market.
Anti-Asthmatics And COPD Drugs Market Categorization By Product Type And Application
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Anti-Asthmatics And COPD Drugs Market Trends: What Is Shaping Future Industry Growth?
Major players in the anti-asthmatics and COPD drugs market are increasingly prioritizing technological innovation, particularly through the development of next-generation propellant inhalers, in response to growing demand for eco-friendly and patient-centric respiratory treatments. This advanced propellant technology replaces conventional hydrofluoroalkane (HFA) propellants with alternatives that feature near-zero Global Warming Potential (GWP), thereby significantly lowering the carbon footprint of pressurized metered-dose inhalers (pMDIs) while preserving drug delivery effectiveness. A notable example occurred in May 2025, when AstraZeneca plc, a UK-based biopharmaceutical firm, introduced Trixeo Aerosphere—a novel fixed-dose triple-combination therapy for COPD that combines budesonide, glycopyrronium, and formoterol fumarate, now administered using this next-generation propellant. This pMDI achieves bioequivalence with earlier formulations, maintains its well-established safety and efficacy profile, and delivers a 99.9% reduction in GWP relative to traditional propellants. By supporting sustainable healthcare practices without sacrificing clinical performance, Trixeo Aerosphere offers patients requiring inhaled respiratory therapy an effective, low-carbon-footprint solution.
Anti-Asthmatics And COPD Drugs Market Company Landscape And Strategic Competition
Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.
Access The Complete Anti-Asthmatics And COPD Drugs Market Report:
Anti-Asthmatics And COPD Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2025. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
